On October 14th 2022, FDA awarded the Rare Paediatric Disease (RPD) designation to BOOST Pharma for its novel cell therapy for the treatment of children suffering from Osteogenesis Imperfecta (OI). OI is a serious rare genetic disease that can lead to severe physical and functional disability, and for which there is currently no approved therapy. The RPD designation allows BOOST Pharma to receive a priority review voucher (at the time of marketing authorization) that can expedite product approval. RPD designation follows the recently awarded Orphan Drug Designation in both Europe and USA.
